mRNA profiling of blood platelets for cancer diagnostics

Published: 30-08-2016
Last updated: 16-04-2024

To validate and improve our blood-based pan-cancer screening test to make it applicable for clinical use

Ethical review	Approved WMO
Status	Recruiting
Health condition type	Other condition
Study type	Observational invasive

Summary

ID

NL-OMON43314

Source
ToetsingOnline

Brief title
Pan-cancer diagnostics

Condition

- Other condition

Synonym
cancer

Health condition

alle type tumoren

Research involving
Human

Sponsors and support

Primary sponsor: Neurochirurgie
Source(s) of monetary or material Support: KWF

Intervention

Keyword: Cancer, Diagnostics, Platelets

Outcome measures

Primary outcome

RNA profiles from blood platelets

Secondary outcome

Not applicable

Study description

Background summary

Cancer is still a disease which can not be overcome by everyone. Often this is due to the late detection of the tumor. At a moment there are already metastases the chances of curing this disease are extremely low. Much improvement can be made by detecting cancer in a earlier stage. This requires a new way of screening. Recent research has shown that tumors leave traces behind in the bloodstream. If we can find these traces in blood from patients it is possible to distinguish healthy people from cancer patients. Our research has shown that platelets from cancer patients have a different genetic content compared to healthy donors. Because of this different genetic material, in this case RNA, we are able to distinguish multiple tumor types from healthy people. With this method, we hope to discover cancer at an earlier stage so that more patients can be cured of cancer.

Study objective

To validate and improve our blood-based pan-cancer screening test to make it applicable for clinical use

Study design

Cancer patient samples are already being collected. This study is focused on obtaining enough healthy controls. Volunteers need to be willing to donate blood once. Further storage and processing will all be done completely anonymous. The RNA profiles from platelets will be used to further develop our diagnostic tests.

Study burden and risks

Neglectable, one blood draw on a healthy population

Contacts

Public
Selecteer

De Boelelaan 1117
Amsterdam 1081HV
NL
Scientific
Selecteer

De Boelelaan 1117
Amsterdam 1081HV
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

age 18 and up

Exclusion criteria

a history of cancer

Study design

Design

Study type: Observational invasive

Masking:	Open (masking not used)
Control:	Uncontrolled
Primary purpose:	Diagnostic

Recruitment

NL

Recruitment status:	Recruiting
Start date (anticipated):	11-10-2016
Enrollment:	1300
Type:	Actual

Ethics review

Approved WMO

Date:	30-08-2016
Application type:	First submission
Review commission:	METC Amsterdam UMC

Approved WMO

Date:	25-11-2016
Application type:	Amendment
Review commission:	METC Amsterdam UMC

Approved WMO

Date:	20-12-2017
Application type:	Amendment
Review commission:	METC Amsterdam UMC

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
CCMO	NL57559.029.16